By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Saladax today announced a deal with InyDia Labs for the distribution of the My5-FU test in Spain and Portugal.

Saladax's My5-FU test measures levels of the oncology drug 5-fluorouracil, or 5-FU, in the blood of cancer patients, and the deal with InyDia makes it the exclusive provider of My5-FU test kits in the two countries.

Financial terms of the deal were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.